liu.seSearch for publications in DiVA
Endre søk
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Long-term outcomes of thoracic transplant recipients following conversion to everolimus with reduced calcineurin inhibitor in a multicenter, open-label, randomized trial
Department of Cardiology, Oslo University Hospital Rikshospitalet, Oslo, Norway; Faculty of Medicine, K.G. Jebsen Cardiac Research Centre and Center for Heart Failure Research, University of Oslo, Oslo, Norway.
Department of Cardiology, Aarhus University Hospital, Skejby, Aarhus, Denmark.
Department of Cardiology, Rigshospitalet, Copenhagen, Denmark.
Department of Respiratory Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden.
Vise andre og tillknytning
2016 (engelsk)Inngår i: Transplant International, ISSN 0934-0874, E-ISSN 1432-2277, Vol. 29, nr 7, s. 819-829Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

The NOCTET study randomized 282 patients ≥1 year after heart or lung transplantation to continue conventional calcineurin inhibitor (CNI) therapy or to start everolimus with reduced-exposure CNI. Last follow-up, at ≥5 years postrandomization (mean: 5.6 years) was attended by 72/140 everolimus patients (51.4%) and 91/142 controls (64.1%). Mean measured GFR remained stable in the everolimus group from randomization (51.3 ml/min) to last visit (51.4 ml/min) but decreased in controls (from 50.5 ml/min to 45.3 ml/min) and was significantly higher with everolimus at last follow-up (P = 0.004). The least squares mean (SE) change from randomization was -1.5 (1.7)ml/min with everolimus versus -7.2 (1.7)ml/min for controls (difference: 5.7 [95% CI 1.7; 9.6]ml/min; P = 0.006). The difference was accounted for by heart transplant patients (difference: 6.9 [95% 2.3; 11.5]ml/min; P = 0.004). Lung transplant patients showed no between-group difference at last follow-up. Rates of rejection, death, and major cardiac events were similar between groups, as was graft function. Pneumonia was more frequent with everolimus (18.3% vs. 6.4%). In conclusion, introducing everolimus in maintenance heart transplant patients, with reduced CNI, achieves a significant improvement in renal function which is maintained for at least 5 years, but an early renal benefit in lung transplant patients was lost. Long-term immunosuppressive efficacy was maintained.

sted, utgiver, år, opplag, sider
Wiley-Blackwell Publishing Inc., 2016. Vol. 29, nr 7, s. 819-829
Emneord [en]
calcineurin inhibitor, certican, cyclosporine, everolimus, heart, lung, randomized, renal impairment, tacrolimus, transplantation
HSV kategori
Identifikatorer
URN: urn:nbn:se:liu:diva-130205DOI: 10.1111/tri.12783ISI: 000379691200009PubMedID: 27067532OAI: oai:DiVA.org:liu-130205DiVA, id: diva2:948976
Merknad

Funding agencies: Novartis Scandinavia

Tilgjengelig fra: 2016-07-14 Laget: 2016-07-14 Sist oppdatert: 2017-11-28bibliografisk kontrollert

Open Access i DiVA

Fulltekst mangler i DiVA

Andre lenker

Forlagets fulltekstPubMed

Person

Jansson, Kjell

Søk i DiVA

Av forfatter/redaktør
Jansson, Kjell
Av organisasjonen
I samme tidsskrift
Transplant International

Søk utenfor DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric

doi
pubmed
urn-nbn
Totalt: 51 treff
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf